#USA #Tampa Bay #AI Innovation #AINGENS #Ome Ogbru

Innovating Life Sciences: Ome Ogbru's Approach to Overcoming Workflow Challenges with AI

In the constantly evolving landscape of life sciences, the need for breakthrough innovations is undeniable. Yet, a significant portion of the industry grapples with inefficient workflows and manual processes that consume valuable time and resources. Ome Ogbru, PharmD, the CEO and founder of AINGENS, asserts that the primary issue plaguing the pharmaceutical sector is not the lack of intelligence, but rather how the administrative work is conducted.

During his conversation on the podcast Disruption Interruption with host Karla Jo Helms, Ogbru elaborates on this issue, indicating that life sciences teams often find themselves entangled in cumbersome systems. He emphasizes that procurement processes can be excessively slow, with teams potentially taking months or even years to identify and implement the necessary software solutions. "It could take you a year to a couple of years to actually get your solution," he explains, noting that the final outcome often fails to meet initial expectations.

The burden of these workflow inefficiencies disproportionately affects the professionals whose expertise could be better utilized elsewhere. Instead of concentrating on their core scientific roles, these trained experts find themselves entangled in prolonged documentation, laborious literature searches, and tedious formatting tasks. Ogbru points out that even experienced professionals can spend hours, if not days, searching through platforms like PubMed, which boasts over 35 million citations, to locate relevant articles answering specific research questions. This inefficiency underscores the human limitations inherent in the process, as Ogbru says, "You could miss things. We are human, and we're not perfect."

The complexities of the regulatory environment further complicate these challenges. Teams within life sciences not only need to adhere to scientific standards but also navigate a web of regulatory frameworks and promotional guidelines that dictate what can and cannot be communicated. Consequently, critical information often reaches patients, clinicians, and researchers later than desired, rather than fostering timely and informed decision-making.

The Role of AI in Life Sciences

While generative AI has emerged as a potential solution to these ongoing issues, Ogbru is clear that the technology alone is not sufficient. Instead, its success hinges on appropriately integrating it with deep domain expertise and workflows crafted specifically for scientific endeavors. Reflecting on his initial experiences with AI, Ogbru shares how he encountered challenges while testing ChatGPT and concluded that it wasn't the technology's fault—it was his lack of understanding of how to leverage it effectively.

This realization led to the development of AINGENS, which focuses on creating AI tools that address specific pain points faced by life science professionals. Their flagship product, the Medical Affairs Content Generator (MACG), is designed to empower experts in the field. Ogbru emphasizes that the platform allows the user to maintain control of the scientific narrative, positioning them as the driver of their own expertise. The platform streamlines mundane tasks like literature searches, drafting, and formatting while enabling experts to apply their regulatory knowledge and contextual understanding.

Ogbru believes that when utilized correctly, AI can achieve remarkable outcomes, enhancing the efficiency of life sciences without sacrificing compliance or accuracy. By reducing the time spent on administrative burdens, professionals can shift their focus back to critical scientific judgment and communication, thereby fostering a more effective and responsive life sciences environment.

A Vision for the Future

Looking ahead, Ogbru's vision extends beyond mere productivity gains. He aims for the life sciences sector to accelerate not only in efficiency but also in the dissemination of accurate information, effectively countering the spread of misinformation. Recalling instances where patients rejected proven medical treatments due to false claims, he asserts that providing reliable scientific data is crucial in today's landscape.

Dr. Ogbru's mission is clear: not only to automate processes within the industry but to facilitate the transformation of scientific data into actionable knowledge that can be better understood by the public, healthcare professionals, and researchers alike. As AINGENS continues to pioneer evidence-first AI platforms, it stands at the forefront of reshaping how scientific communication is conducted, ensuring that accuracy and compliance remain cornerstones of its operations.

Learn more about AINGENS and the innovations brought by Ome Ogbru at AINGENS Website and listen to the full episode of Disruption Interruption for an in-depth discussion on these pivotal topics.